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BACKGROUND: As a result of increasing cost con-
sciousness in the health care system, pharmaceutical
manufacturers have come under pressure to demonstrate
the pharmacoeconomic benefits of their products to
health care providers and payers. OBJECTIVE: To ana-
lyze the content of economic and health-related-quality-
of-life appeals in drug advertisements in primary care and
specialty journals. METHODS: Advertisements from
specialty and primary care journals from June 1997 to
June 1999 were analyzed. Each message was classified by
the content of the appeal as one of eight economic or
quality-of-life categories: compliance; direct or indirect
economic; patient satisfaction; overall well being; or
physical, social or psychological function. Appeals were
also classified as explicit or implicit depending on their
use of economic or “quality of life” terms (e.g. “cost-
effective”). Data were also collected on which type of ref-
erence the appeal cited: none, data on file or published
reference. RESULTS: Sixty-one advertisements were in-
cluded in the analysis with a total of eighty messages. Ap-
peals were mainly implicit (85%) and related to direct
economic messages. Specialty journals had relatively
more messages appealing to compliance (29% vs. 8%)
while primary care journals had relatively more messages
appealing to psychological function (24% vs. 4%). Most
appeals cited a published reference to substantiate their
message (56%), but 24% of appeals cited no reference.
Primary care journals were more likely to cite published
references than specialty journals (66% vs. 47%). CON-
CLUSION: In the absence of clearly delineated regula-
tion by the FDA governing the advertising of economic
or quality-of-life-related messages, the pharmaceutical in-
dustry has focused on implicit messages, avoiding overt
appeals to “cost-effective”, “cost-benefit”, “cost-utility”,
“QALY” or “quality of life”.
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OBJECTIVE: To determine the impact of pharmacist in-
tervention on various patient outcomes. METHODS:
201 patients belonging to one medical group were di-
vided into the experimental group (N  54) and the com-
parator group (N  147). 353 patients belonging to a
second medical group served as the control group. All pa-
tients were sent a baseline survey and a follow-up survey
after 6 months to gather data on demographics, compli-
ance, quality of care, satisfaction with pharmacy care and
disease specific quality of life. During the 6 month pe-
riod, the experimental group received specialized phar-
macist’s services, while the others received usual care.
Clinical data, compliance from prescription claims and
health care utilization data were collected separately. RE-
SULTS: Patient satisfaction with pharmacy services sig-
nificantly improved at follow-up for the experimental
group. The increase in satisfaction at follow-up was sig-
nificantly higher in the experimental group compared to
the comparator as well as the control groups. HbA1c
scores for diabetic patients were significantly improved in
the experimental (7.8 down to 6.7) group. Adherence to
some of the HEDIS guidelines was significantly higher in
the experimental group compared to the comparator
group. Percentage of high compliers (self-reported Morisky
score) significantly doubled at follow-up in the experi-
mental group ( 24.6% up to 52%) and percentage of low
compliers significantly decreased at follow-up (73.6%
down to 49.1%). The number of drug therapy problems
were detected and reduced by pharmacists’ intervention
in the experimental group. Pharmacists were also able to
successfully improve patient health behaviors related to
medication use in the experimental group. CONCLU-
SION: The pharmacists were successful in improving pa-
tient outcomes, thereby providing better patient care.
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Age related macular degeneration is the leading cause of
legal blindness among those over 50 years old in the
Western world and is estimated to affect 20–37% of peo-
ple aged over 75 years. The only treatment option to
date, for the more severe wet form, is laser therapy, but is
appropriate for only about 20% of cases. There are sev-
eral new therapies under investigation, including photo-
dynamic therapy (PDT) with verteporfin, an intravenous
infusion followed by timed activation of the verteporfin
with a specific light source. OBJECTIVE: To estimate ef-
fects of verteporfin in terms of vision years gained, a
measure suitable for economic evaluation. METHODS:
Data came from the one year follow-up of a two year
Phase III clinical trial of 609 patients randomized verte-
porfin or placebo. The analysis included only those with
predominantly Classic CNV secondary to AMD as this
subgroup will be the one initially indicated for therapy.
Survival analyses (controlling for baseline vision, age,
gender and prior treatment) using a Weibull parametric
